Company Encyclopedia
View More
name
ISHRS MSCI Israel Capped
EIS.US
News
View More

Teva Pharmaceutical Industries (NYSE:TEVA) Downgraded by Wall Street Zen to Buy

Wall Street Zen lowered Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a report on Saturday.

Market Beat·
US
TEVA
-1.29%
Market Beat·
US
TEVA
-1.29%

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 | TEVA Stock News

Teva Pharmaceutical Industries Ltd. will release its fourth quarter 2025 financial results on January 28, 2026, at 7:00 a.m. ET, followed by a conference call and webcast at 8:00 a.m. ET. Participants must register in advance. A replay will be available on Teva's website. The company is focused on innovative biopharmaceuticals and generics, with cautionary notes on forward-looking statements.

StockTitan·
US
TEVA
-1.29%
StockTitan·
US
TEVA
-1.29%

Teva Releases Q4 2025 Aide Memoire | TEVA Stock News

Teva Pharmaceutical Industries Ltd. announced the availability of its Q4 2025 Aide Memoire on its website to assist investors ahead of the fourth quarter results, expected on January 28, 2026. The document includes public information, prior results, and management commentary. Teva cautions about forward-looking statements and associated risks. The company is transforming into a leading biopharmaceutical firm with a strong generics business.

StockTitan·
US
TEVA
-1.29%
StockTitan·
US
TEVA
-1.29%

Soros Fund Management LLC Cuts Stock Holdings in CyberArk Software Ltd. $CYBR

Soros Fund Management LLC reduced its stake in CyberArk Software Ltd. by 65.4% in Q2. Analysts have mixed ratings on CYBR, with an average "Hold" rating and a price target of $455.96. CYBR stock opened at $459.81, with a 52-week range of $288.63-$526.19. The company reported Q3 revenue of $342.84 million, up 42.8% year-over-year.

Market Beat·
US
CYBR
+0.66%
Market Beat·
US
CYBR
+0.66%

Top Executives Unload Massive Shares of Teva Pharmaceutical Stock!

Top executives at Teva Pharmaceutical, Richard Daniell and Mark Sabag, sold significant shares worth over $9.5 million combined. Teva extended its Revolving Facility Agreement's maturity date to April 2028, amending financial covenants to enhance flexibility. Despite positive technical momentum and earnings insights, analysts highlight financial challenges, emphasizing debt reduction and profitability for stability. Spark rates TEVA stock as Neutral, noting the company's transitional phase. Teva's YTD price performance is 39.91%, with a market cap of $33.02B.

Tip Ranks·
US
TEVA
-1.29%
Tip Ranks·
US
TEVA
-1.29%
© 2025 Longbridge｜Disclaimer